Mara Goldstein
Stock Analyst at Clear Street
(0.17)
# 4,632
Out of 4,988 analysts
1004
Total ratings
34.7%
Success rate
-4.5%
Average return
Main Sectors:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Reiterated: Buy | $37 | $24.95 | +48.30% | 1 | Sep 9, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | $8 | $4.21 | +90.02% | 1 | Sep 4, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Buy | $31 | $17.85 | +73.67% | 2 | Sep 3, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $45 → $32 | $8.03 | +298.51% | 4 | Aug 25, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $26 | $4.35 | +497.70% | 1 | Aug 3, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $32 → $30 | $11.73 | n/a | 5 | Aug 18, 2025 | |
| INCY Incyte | Reiterated: Hold | $77 → $74 | $125.31 | n/a | 73 | Aug 4, 2025 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $30 | $10.25 | n/a | 50 | Feb 8, 2024 | |
| MRK Merck & Co. | Reiterated: Buy | $138 | $146.87 | n/a | 121 | Feb 5, 2024 | |
| ADAPY Adaptimmune Therapeutics plc | Reiterated: Buy | $9 | $0.0225 | n/a | 47 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 → $42 | $25.24 | n/a | 79 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $17.62 | n/a | 3 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $3.60 | n/a | 31 | Jan 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $1.94 | n/a | 54 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $59 → $50 | $24.72 | n/a | 55 | Jan 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $175 → $7 | $0.0002 | n/a | 23 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $14.77 | n/a | 12 | Jan 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $7.44 | n/a | 44 | Jan 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.53 | n/a | 49 | Jan 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $2.76 | n/a | 51 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.08 | n/a | 33 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $4.48 | n/a | 8 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3.5 | $12.56 | n/a | 49 | Dec 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 → $5 | $67.10 | n/a | 25 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $32.09 | n/a | 26 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 | $0.9157 | n/a | 7 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.1288 | n/a | 2 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $129.85 | n/a | 5 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $33.46 | n/a | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $7.76 | n/a | 1 | Jun 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $14 | $68.78 | n/a | 17 | Sep 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 | $2.78 | n/a | 27 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 → $25 | $1.88 | n/a | 14 | May 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.0001 | n/a | 3 | Apr 18, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $135 → $45 | $38.24 | n/a | 24 | Apr 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $3.42 | n/a | 18 | Mar 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12.11 | $0.81 | n/a | 1 | Dec 29, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $207.78 | n/a | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $277 | $215.50 | n/a | 1 | Apr 28, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $16.03 | n/a | 8 | Apr 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $0.6526 | n/a | 1 | Apr 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 → $14 | $1.19 | n/a | 4 | Apr 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.36 | n/a | 2 | Oct 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.001 | n/a | 9 | Apr 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $2 | $11.49 | n/a | 8 | Dec 8, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $4 → $2 | $0.0001 | n/a | 2 | Jan 24, 2014 |
Beam Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $37
Current: $24.95
Upside: +48.30%
Molecular Partners AG
Sep 4, 2026
Reiterated: Buy
Price Target: $8
Current: $4.21
Upside: +90.02%
Summit Therapeutics
Sep 3, 2026
Reiterated: Buy
Price Target: $31
Current: $17.85
Upside: +73.67%
REGENXBIO
Aug 25, 2026
Reiterated: Buy
Price Target: $45 → $32
Current: $8.03
Upside: +298.51%
Wave Life Sciences
Aug 3, 2026
Reiterated: Buy
Price Target: $26
Current: $4.35
Upside: +497.70%
Kura Oncology
Aug 18, 2025
Reiterated: Buy
Price Target: $32 → $30
Current: $11.73
Upside: n/a
Incyte
Aug 4, 2025
Reiterated: Hold
Price Target: $77 → $74
Current: $125.31
Upside: n/a
Iovance Biotherapeutics
Feb 8, 2024
Reiterated: Buy
Price Target: $30
Current: $10.25
Upside: n/a
Merck & Co.
Feb 5, 2024
Reiterated: Buy
Price Target: $138
Current: $146.87
Upside: n/a
Adaptimmune Therapeutics plc
Jan 31, 2024
Reiterated: Buy
Price Target: $9
Current: $0.0225
Upside: n/a
Jan 29, 2024
Reiterated: Buy
Price Target: $51 → $42
Current: $25.24
Upside: n/a
Jan 24, 2024
Reiterated: Buy
Price Target: $45
Current: $17.62
Upside: n/a
Jan 23, 2024
Reiterated: Buy
Price Target: $12
Current: $3.60
Upside: n/a
Jan 22, 2024
Reiterated: Buy
Price Target: $12
Current: $1.94
Upside: n/a
Jan 21, 2024
Rated: Buy
Price Target: $59 → $50
Current: $24.72
Upside: n/a
Jan 16, 2024
Reiterated: Buy
Price Target: $175 → $7
Current: $0.0002
Upside: n/a
Jan 15, 2024
Reiterated: Buy
Price Target: $7
Current: $14.77
Upside: n/a
Jan 15, 2024
Reiterated: Buy
Price Target: $36
Current: $7.44
Upside: n/a
Jan 12, 2024
Reiterated: Buy
Price Target: $8
Current: $2.53
Upside: n/a
Jan 5, 2024
Reiterated: Hold
Price Target: $2
Current: $2.76
Upside: n/a
Jan 4, 2024
Reiterated: Buy
Price Target: $8
Current: $1.08
Upside: n/a
Dec 12, 2023
Reiterated: Buy
Price Target: $20
Current: $4.48
Upside: n/a
Dec 10, 2023
Rated: Hold
Price Target: $3.5
Current: $12.56
Upside: n/a
Nov 8, 2023
Rated: Hold
Price Target: $6 → $5
Current: $67.10
Upside: n/a
Aug 4, 2023
Rated: Hold
Price Target: n/a
Current: $32.09
Upside: n/a
May 16, 2022
Reiterated: Hold
Price Target: $2
Current: $0.9157
Upside: n/a
Feb 18, 2022
Rated: Hold
Price Target: n/a
Current: $0.1288
Upside: n/a
Oct 1, 2021
Reiterated: Buy
Price Target: n/a
Current: $129.85
Upside: n/a
Jun 8, 2021
Reiterated: Buy
Price Target: n/a
Current: $33.46
Upside: n/a
Jun 22, 2020
Reiterated: Buy
Price Target: $24
Current: $7.76
Upside: n/a
Sep 20, 2018
Initiated Coverage: Buy
Price Target: $10 → $14
Current: $68.78
Upside: n/a
Jun 13, 2018
Reiterated: Hold
Price Target: $6
Current: $2.78
Upside: n/a
May 1, 2018
Reiterated: Buy
Price Target: $18 → $25
Current: $1.88
Upside: n/a
Apr 18, 2018
Reiterated: Buy
Price Target: $5
Current: $0.0001
Upside: n/a
Apr 16, 2018
Downgraded: Hold
Price Target: $135 → $45
Current: $38.24
Upside: n/a
Mar 19, 2018
Reiterated: Buy
Price Target: $12
Current: $3.42
Upside: n/a
Dec 29, 2017
Reiterated: Buy
Price Target: $12.11
Current: $0.81
Upside: n/a
Dec 1, 2017
Rated: Buy
Price Target: $13
Current: $207.78
Upside: n/a
Apr 28, 2017
Reiterated: Hold
Price Target: $277
Current: $215.50
Upside: n/a
Apr 13, 2017
Reiterated: Hold
Price Target: $7
Current: $16.03
Upside: n/a
Apr 13, 2017
Reiterated: Buy
Price Target: $15
Current: $0.6526
Upside: n/a
Apr 13, 2017
Reiterated: Hold
Price Target: $2 → $14
Current: $1.19
Upside: n/a
Oct 7, 2016
Reiterated: Buy
Price Target: $7
Current: $1.36
Upside: n/a
Apr 7, 2016
Reiterated: Buy
Price Target: n/a
Current: $0.001
Upside: n/a
Dec 8, 2015
Upgraded: Hold
Price Target: $2
Current: $11.49
Upside: n/a
Jan 24, 2014
Downgraded: Hold
Price Target: $4 → $2
Current: $0.0001
Upside: n/a